Type I interferon sensing unlocks dormant adipocyte inflammatory potential

Type I interferon in organ-targeted autoimmune and inflammatory diseases

A significant role for IFNα in the pathogenesis of systemic lupus erythematosus is well supported, and clinical trials of anti-IFNα monoclonal antibodies are in progress in this disease. In other autoimmune diseases characterized by substantial inflammation and tissue destruction, the role of type I interferons is less clear. Gene expression analysis of peripheral blood cells from patients with...

Type I Interferon: Potential Therapeutic Target for Psoriasis?

BACKGROUND Psoriasis is an immune-mediated disease characterized by aberrant epidermal differentiation, surface scale formation, and marked cutaneous inflammation. To better understand the pathogenesis of this disease and identify potential mediators, we used whole genome array analysis to profile paired lesional and nonlesional psoriatic skin and skin from healthy donors. METHODOLOGY/PRINCIP...

Interfering with type I Interferon

Scientists have been investigating the critical role type 1 interferons (IFN-I) play in controlling viral infections for more than 50 y. Common pathogen motifs present on viral particles trigger intracellular and membrane-associated pattern recognition receptors, leading to the production of IFN-I and rapid expression of interferon stimulated genes (ISIGs). ISIGs encode proteins with direct ant...

Host histone acetylation unlocks HDAC inhibitor potential

Hantavirus Regulation of Type I Interferon Responses

Hantaviruses primarily infect human endothelial cells (ECs) and cause two highly lethal human diseases. Early addition of Type I interferon (IFN) to ECs blocks hantavirus replication and thus for hantaviruses to be pathogenic they need to prevent early interferon induction. PHV replication is blocked in human ECs, but not inhibited in IFN deficient VeroE6 cells and consistent with this, infecti...